Global Meningococcal Vaccines Market Forecast and Analysis (2019-2026), by Types, by End User, and, by Geography.

Global Meningococcal Vaccines Market was valued at USD xx million in 2018 and is expected to reach at USD xx million by 2026 at a CAGR of xx% over forecast period 2019-2026. To know about the Research Methodology :- Request Free Sample Report Meningococcal vaccines are used to treat meningitis caused by bacterium N. meningitides. The major factors for the growth of the meningococcal vaccines market include an increase in public-private partnerships to support the development of vaccines at low cost, and rising immunization programs and government initiatives. Increasing awareness level of diseases and their vaccines also drives the market for meningococcal vaccines over forecast period. World Health Organization is promoting strategies for prevention of meningitis and is hoping to introduce this vaccine in a moderate or high rate of disease countries of African region, which are suffering from meningitis and they hope to achieve. This would provide growth opportunities in this market. However, the maintenance of cold chain for the delivery of vaccines leads to rise in cost of vaccination, is expected to restrain the market growth.Global Meningococcal Vaccines Market is segmented by types, by end users and by region. By types market is segmented into various vaccines such as bivalent, quadrivalent, Serogroup A, Serogroup B, and Serotype X. Quadrivalent segment is expected to exhibit highest market share at a CAGR of xx% over forecast period owing to the presence of high unmet needs and lack of availability of alternate vaccines. Various brands such as Mentactra, Menveo, Trumenba and Mentlibrix and Menoveo are available in the market for the treatment of meningococcal. By geography, Global Meningococcal Vaccines Market is segmented into APAC, North America, Europe, MEA& Africa and Latin America. North America is expected to lead the global meningococcal market thanks to an increasing government interventions and prevention programs, research and development initiatives by various manufacturers. In Canada and the United States the vaccines effective against all four types of meningococcus are recommended routinely for teenagers and others who are at high risk.Moreover, Asia-Pacific is expected to be the fastest growing market due to low manufacturing cost and increasing healthcare spending. Key players operating in this market are Neuron Biotech, Baxter international, Pfizer Inc., Novartis International, Sanofi S.A., JN-International Medical Corporation, Biomed Pvt. Ltd., and Serum Institute of India Ltd. These key players are using various organic and inorganic growth strategies such as merger and acquisition, expansion, strategic alliances, new product launches, research and development to enhance their business operations and regional presence. The objective of the report is to present a complete calculation of the Global Meningococcal Vaccines Market and contains thoughtful insights, historical data, facts, industry-validated market data and plans with a suitable set of assumptions and methodology. The report also helps in the Global Meningococcal Vaccines Market is a dynamic structure by identifying and analyzing the market segments and project the global market size. The additional, report also focuses on the competitive analysis of key player’s by-product, financial position, price, product portfolio, growth strategies, and regional presence. The report also provides PEST analysis, PORTER’s analysis, and SWOT analysis to address the question of shareholders to prioritizing the efforts and investment shortly to the emerging segment in the Global Meningococcal Vaccines Market. The report study has analyzed revenue impact of covid-19 pandemic on the sales revenue of market leaders, market followers and disrupters in the report and same is reflected in our analysis.

Scope of Global Meningococcal Vaccines Market: Inquire before buying

Global Meningococcal Vaccines Market by Types

• Quadrivalent vaccines • Bivalent vaccines • Serogroup A • Serogroup B • Serogroup X

Global Meningococcal Vaccines Market by Geography

• North America • Europe • Asia-pacific • Latin America • MEA& Africa

Global Meningococcal Vaccines Market by End Users

• Children • Preteens or Teens • Adults

Global Meningococcal Vaccines Market Major players

• Neuron Biotech • Baxter international • Pfizer Inc. • Novartis International • Sanofi S.A. • JN-International Medical Corporation • Biomed Pvt. Ltd. • Serum Institute of India Ltd. • GlaxoSmithKline plc. • Merck & Co., Inc. • MenQuadfi • Walvax Biotechnology Co., Ltd. • Bio-Med Pvt. Ltd. • Chongqing Zhifei Biological Products Co., Ltd. • Hualan Biological Engineering, Inc. • Incepta Pharmaceuticals Ltd.
Global Meningococcal Vaccines Market 1. Preface 1.1. Report Scope and Market Segmentation 1.2. Research Highlights 1.3. Research Objectives 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: Global Meningococcal vaccines Market, by Market Value (US$ Mn) and Volume(Ton) 4. Market Overview 4.1. Introduction 4.2. Market Indicator 4.2.1. Drivers 4.2.2. Restraints 4.2.3. Opportunities 4.2.4. Challenges 4.3. Porter’s Analysis 4.4. Value Chain Analysis 4.5. Market Risk Analysis 4.6. SWOT Analysis 4.7. Industry Trends and Emerging Technologies 5. Supply Side and Demand Side Indicators 6. Global Meningococcal vaccines Market Analysis and Forecast 6.1. Global Meningococcal vaccines Market Size & Y-o-Y Growth Analysis 6.1.1. North America 6.1.2. Europe 6.1.3. Asia Pacific 6.1.4. Middle East & Africa 6.1.5. South America 7. Global Meningococcal vaccines Market Analysis and Forecast, by Type 7.1. Introduction and Definition 7.2. Key Findings 7.3. Global Meningococcal vaccines Market Value Share Analysis, by Type 7.4. Global Meningococcal vaccines Market Size (US$ Mn) Forecast, by Type 7.5. Global Meningococcal vaccines Market Analysis, by Type 7.6. Global Meningococcal vaccines Market Attractiveness Analysis, by Type 8. Global Meningococcal vaccines Market Analysis and Forecast, by End Users 8.1. Introduction and Definition 8.2. Key Findings 8.3. Global Meningococcal vaccines Market Value Share Analysis, by End Users 8.4. Global Meningococcal vaccines Market Size (US$ Mn) Forecast, by End Users 8.5. Global Meningococcal vaccines Market Analysis, by End Users 8.6. Global Meningococcal vaccines Market Attractiveness Analysis, by End Users 9. Global Meningococcal vaccines Market Analysis, by Region 9.1. Global Meningococcal vaccines Market Value Share Analysis, by Region 9.2. Global Meningococcal vaccines Market Size (US$ Mn) Forecast, by Region 9.3. Global Meningococcal vaccines Market Attractiveness Analysis, by Region 10. North America Meningococcal vaccines Market Analysis 10.1. Key Findings 10.2. North America Meningococcal vaccines Market Overview 10.3. North America Meningococcal vaccines Market Value Share Analysis, by Type 10.4. North America Meningococcal vaccines Market Forecast, by Type 10.4.1. Quadrivalent vaccines 10.4.2. Bivalent vaccines 10.4.3. Serogroup A 10.4.4. Serogroup B 10.4.5. Serogroup X 10.5. North America Meningococcal vaccines Market Value Share Analysis, by End Users 10.6. North America Meningococcal vaccines Market Forecast, by End Users 10.6.1. Children 10.6.2. Preteens or Teens 10.6.3. Adults 10.7. North America Meningococcal vaccines Market Value Share Analysis, by Country 10.8. North America Meningococcal vaccines Market Forecast, by Country 10.8.1. U.S. 10.8.2. Canada 10.9. North America Meningococcal vaccines Market Analysis, by Country 10.10. U.S. Meningococcal vaccines Market Forecast, by Type 10.10.1. Quadrivalent vaccines 10.10.2. Bivalent vaccines 10.10.3. Serogroup A 10.10.4. Serogroup B 10.10.5. Serogroup X 10.11. U.S. Meningococcal vaccines Market Forecast, by End Users 10.11.1. Children 10.11.2. Preteens or Teens 10.11.3. Adults 10.12. Canada Meningococcal vaccines Market Forecast, by Type 10.12.1. Quadrivalent vaccines 10.12.2. Bivalent vaccines 10.12.3. Serogroup A 10.12.4. Serogroup B 10.12.5. Serogroup X 10.13. Canada Meningococcal vaccines Market Forecast, by End Users 10.13.1. Children 10.13.2. Preteens or Teens 10.13.3. Adults 10.14. North America Meningococcal vaccines Market Attractiveness Analysis 10.14.1. By Type 10.14.2. By End Users 10.15. PEST Analysis 10.16. Key Trends 10.17. Key Development 11. Europe Meningococcal vaccines Market Analysis 11.1. Key Findings 11.2. Europe Meningococcal vaccines Market Overview 11.3. Europe Meningococcal vaccines Market Value Share Analysis, by Type 11.4. Europe Meningococcal vaccines Market Forecast, by Type 11.4.1. Quadrivalent vaccines 11.4.2. Bivalent vaccines 11.4.3. Serogroup A 11.4.4. Serogroup B 11.4.5. Serogroup X 11.5. Europe Meningococcal vaccines Market Value Share Analysis, by End Users 11.6. Europe Meningococcal vaccines Market Forecast, by End Users 11.6.1. Children 11.6.2. Preteens or Teens 11.6.3. Adults 11.7. Europe Meningococcal vaccines Market Value Share Analysis, by Country 11.8. Europe Meningococcal vaccines Market Forecast, by Country 11.8.1. Germany 11.8.2. U.K. 11.8.3. France 11.8.4. Italy 11.8.5. Spain 11.8.6. Rest of Europe 11.9. Europe Meningococcal vaccines Market Analysis, by Country 11.10. Germany Meningococcal vaccines Market Forecast, by Type 11.10.1. Quadrivalent vaccines 11.10.2. Bivalent vaccines 11.10.3. Serogroup A 11.10.4. Serogroup B 11.10.5. Serogroup X 11.11. Germany Meningococcal vaccines Market Forecast, by End Users 11.11.1. Children 11.11.2. Preteens or Teens 11.11.3. Adults 11.12. U.K. Meningococcal vaccines Market Forecast, by Type 11.12.1. Quadrivalent vaccines 11.12.2. Bivalent vaccines 11.12.3. Serogroup A 11.12.4. Serogroup B 11.12.5. Serogroup X 11.13. U.K. Meningococcal vaccines Market Forecast, by End Users 11.13.1. Children 11.13.2. Preteens or Teens 11.13.3. Adults 11.14. France Meningococcal vaccines Market Forecast, by Type 11.14.1. Quadrivalent vaccines 11.14.2. Bivalent vaccines 11.14.3. Serogroup A 11.14.4. Serogroup B 11.14.5. Serogroup X 11.15. France Meningococcal vaccines Market Forecast, by End Users 11.15.1. Children 11.15.2. Preteens or Teens 11.15.3. Adults 11.16. Italy Meningococcal vaccines Market Forecast, by Type 11.16.1. Quadrivalent vaccines 11.16.2. Bivalent vaccines 11.16.3. Serogroup A 11.16.4. Serogroup B 11.16.5. Serogroup X 11.17. Italy Meningococcal vaccines Market Forecast, by End Users 11.17.1. Children 11.17.2. Preteens or Teens 11.17.3. Adults 11.18. Spain Meningococcal vaccines Market Forecast, by Type 11.18.1. Quadrivalent vaccines 11.18.2. Bivalent vaccines 11.18.3. Serogroup A 11.18.4. Serogroup B 11.18.5. Serogroup X 11.19. Spain Meningococcal vaccines Market Forecast, by End Users 11.19.1. Children 11.19.2. Preteens or Teens 11.19.3. Adults 11.20. Rest of Europe Meningococcal vaccines Market Forecast, by Type 11.20.1. Quadrivalent vaccines 11.20.2. Bivalent vaccines 11.20.3. Serogroup A 11.20.4. Serogroup B 11.20.5. Serogroup X 11.21. Rest of Europe Meningococcal vaccines Market Forecast, by End Users 11.21.1. Children 11.21.2. Preteens or Teens 11.21.3. Adults 11.22. Europe Meningococcal vaccines Market Attractiveness Analysis 11.22.1. By Type 11.22.2. By End Users 11.23. PEST Analysis 11.24. Key Trends 11.25. Key Development 12. Asia Pacific Meningococcal vaccines Market Analysis 12.1. Key Findings 12.2. Asia Pacific Meningococcal vaccines Market Overview 12.3. Asia Pacific Meningococcal vaccines Market Value Share Analysis, by Type 12.4. Asia Pacific Meningococcal vaccines Market Forecast, by Type 12.4.1. Quadrivalent vaccines 12.4.2. Bivalent vaccines 12.4.3. Serogroup A 12.4.4. Serogroup B 12.4.5. Serogroup X 12.5. Asia Pacific Meningococcal vaccines Market Value Share Analysis, by End Users 12.6. Asia Pacific Meningococcal vaccines Market Forecast, by End Users 12.6.1. Children 12.6.2. Preteens or Teens 12.6.3. Adults 12.7. Asia Pacific Meningococcal vaccines Market Value Share Analysis, by Country 12.8. Asia Pacific Meningococcal vaccines Market Forecast, by Country 12.8.1. China 12.8.2. India 12.8.3. Japan 12.8.4. ASEAN 12.8.5. Rest of Asia Pacific 12.9. Asia Pacific Meningococcal vaccines Market Analysis, by Country 12.10. China Meningococcal vaccines Market Forecast, by Type 12.10.1. Quadrivalent vaccines 12.10.2. Bivalent vaccines 12.10.3. Serogroup A 12.10.4. Serogroup B 12.10.5. Serogroup X 12.11. China Meningococcal vaccines Market Forecast, by End Users 12.11.1. Children 12.11.2. Preteens or Teens 12.11.3. Adults 12.12. India Meningococcal vaccines Market Forecast, by Type 12.12.1. Quadrivalent vaccines 12.12.2. Bivalent vaccines 12.12.3. Serogroup A 12.12.4. Serogroup B 12.12.5. Serogroup X 12.13. India Meningococcal vaccines Market Forecast, by End Users 12.13.1. Children 12.13.2. Preteens or Teens 12.13.3. Adults 12.14. Japan Meningococcal vaccines Market Forecast, by Type 12.14.1. Quadrivalent vaccines 12.14.2. Bivalent vaccines 12.14.3. Serogroup A 12.14.4. Serogroup B 12.14.5. Serogroup X 12.15. Japan Meningococcal vaccines Market Forecast, by End Users 12.15.1. Children 12.15.2. Preteens or Teens 12.15.3. Adults 12.16. ASEAN Meningococcal vaccines Market Forecast, by Type 12.16.1. Quadrivalent vaccines 12.16.2. Bivalent vaccines 12.16.3. Serogroup A 12.16.4. Serogroup B 12.16.5. Serogroup X 12.17. ASEAN Meningococcal vaccines Market Forecast, by End Users 12.17.1. Children 12.17.2. Preteens or Teens 12.17.3. Adults 12.18. Rest of Asia Pacific Meningococcal vaccines Market Forecast, by Type 12.18.1. Quadrivalent vaccines 12.18.2. Bivalent vaccines 12.18.3. Serogroup A 12.18.4. Serogroup B 12.18.5. Serogroup X 12.19. Rest of Asia Pacific Meningococcal vaccines Market Forecast, by End Users 12.19.1. Children 12.19.2. Preteens or Teens 12.19.3. Adults 12.20. Asia Pacific Meningococcal vaccines Market Attractiveness Analysis 12.20.1. By Type 12.20.2. By End Users 12.21. PEST Analysis 12.22. Key Trends 12.23. Key Development 13. Middle East & Africa Meningococcal vaccines Market Analysis 13.1. Key Findings 13.2. Middle East & Africa Meningococcal vaccines Market Overview 13.3. Middle East & Africa Meningococcal vaccines Market Value Share Analysis, by Type 13.4. Middle East & Africa Meningococcal vaccines Market Forecast, by Type 13.4.1. Quadrivalent vaccines 13.4.2. Bivalent vaccines 13.4.3. Serogroup A 13.4.4. Serogroup B 13.4.5. Serogroup X 13.5. Middle East & Africa Meningococcal vaccines Market Value Share Analysis, by End Users 13.6. Middle East & Africa Meningococcal vaccines Market Forecast, by End Users 13.6.1. Children 13.6.2. Preteens or Teens 13.6.3. Adults 13.7. Middle East & Africa Meningococcal vaccines Market Value Share Analysis, by Country 13.8. Middle East & Africa Meningococcal vaccines Market Forecast, by Country 13.8.1. GCC 13.8.2. South Africa 13.8.3. Rest of Middle East & Africa 13.9. Middle East & Africa Meningococcal vaccines Market Analysis, by Country 13.10. GCC Meningococcal vaccines Market Forecast, by Type 13.10.1. Quadrivalent vaccines 13.10.2. Bivalent vaccines 13.10.3. Serogroup A 13.10.4. Serogroup B 13.10.5. Serogroup X 13.11. GCC Meningococcal vaccines Market Forecast, by End Users 13.11.1. Children 13.11.2. Preteens or Teens 13.11.3. Adults 13.12. South Africa Meningococcal vaccines Market Forecast, by Type 13.12.1. Quadrivalent vaccines 13.12.2. Bivalent vaccines 13.12.3. Serogroup A 13.12.4. Serogroup B 13.12.5. Serogroup X 13.13. South Africa Meningococcal vaccines Market Forecast, by End Users 13.13.1. Children 13.13.2. Preteens or Teens 13.13.3. Adults 13.14. Rest of Middle East & Africa Meningococcal vaccines Market Forecast, by Type 13.14.1. Quadrivalent vaccines 13.14.2. Bivalent vaccines 13.14.3. Serogroup A 13.14.4. Serogroup B 13.14.5. Serogroup X 13.15. Rest of Middle East & Africa Meningococcal vaccines Market Forecast, by End Users 13.15.1. Children 13.15.2. Preteens or Teens 13.15.3. Adults 13.16. Middle East & Africa Meningococcal vaccines Market Attractiveness Analysis 13.16.1. By Type 13.16.2. By End Users 13.17. PEST Analysis 13.18. Key Trends 13.19. Key Development 14. South America Meningococcal vaccines Market Analysis 14.1. Key Findings 14.2. South America Meningococcal vaccines Market Overview 14.3. South America Meningococcal vaccines Market Value Share Analysis, by Type 14.4. South America Meningococcal vaccines Market Forecast, by Type 14.4.1. Quadrivalent vaccines 14.4.2. Bivalent vaccines 14.4.3. Serogroup A 14.4.4. Serogroup B 14.4.5. Serogroup X 14.5. South America Meningococcal vaccines Market Value Share Analysis, by End Users 14.6. South America Meningococcal vaccines Market Forecast, by End Users 14.6.1. Children 14.6.2. Preteens or Teens 14.6.3. Adults 14.7. South America Meningococcal vaccines Market Value Share Analysis, by Country 14.8. South America Meningococcal vaccines Market Forecast, by Country 14.8.1. Brazil 14.8.2. Mexico 14.8.3. Rest of South America 14.9. South America Meningococcal vaccines Market Analysis, by Country 14.10. Brazil Meningococcal vaccines Market Forecast, by Type 14.10.1. Quadrivalent vaccines 14.10.2. Bivalent vaccines 14.10.3. Serogroup A 14.10.4. Serogroup B 14.10.5. Serogroup X 14.11. Brazil Meningococcal vaccines Market Forecast, by End Users 14.11.1. Children 14.11.2. Preteens or Teens 14.11.3. Adults 14.12. Mexico Meningococcal vaccines Market Forecast, by Type 14.12.1. Quadrivalent vaccines 14.12.2. Bivalent vaccines 14.12.3. Serogroup A 14.12.4. Serogroup B 14.12.5. Serogroup X 14.13. Mexico Meningococcal vaccines Market Forecast, by End Users 14.13.1. Children 14.13.2. Preteens or Teens 14.13.3. Adults 14.14. Rest of South America Meningococcal vaccines Market Forecast, by Type 14.14.1. Quadrivalent vaccines 14.14.2. Bivalent vaccines 14.14.3. Serogroup A 14.14.4. Serogroup B 14.14.5. Serogroup X 14.15. Rest of South America Meningococcal vaccines Market Forecast, by End Users 14.15.1. Children 14.15.2. Preteens or Teens 14.15.3. Adults 14.16. South America Meningococcal vaccines Market Attractiveness Analysis 14.16.1. By Type 14.16.2. By End Users 14.17. PEST Analysis 14.18. Key Trends 14.19. Key Development 15. Company Profiles 15.1. Market Share Analysis, by Company 15.2. Competition Matrix 15.2.1. Competitive Benchmarking of key players by price, presence, market share, Applications and R&D investment 15.2.2. New Product Launches and Product Enhancements 15.2.3. Market Consolidation 15.2.3.1. M&A by Regions, Investment and Applications 15.2.3.2. M&A Key Players, Forward Integration and Backward Integration 15.3. Company Profiles: Key Players 15.3.1. Neuron Biotech 15.3.1.1. Company Overview 15.3.1.2. Financial Overview 15.3.1.3. Product Portfolio 15.3.1.4. Business Strategy 15.3.1.5. Recent Developments 15.3.1.6. Company Footprint 15.3.2. Baxter international 15.3.3. Pfizer Inc. 15.3.4. Novartis International 15.3.5. Sanofi S.A. 15.3.6. JN-International Medical Corporation 15.3.7. Biomed Pvt. Ltd. 15.3.8. Serum Institute of India Ltd. 15.3.9. GlaxoSmithKline plc. 15.3.10. Merck & Co., Inc. 15.3.11. MenQuadfi 15.3.12. Walvax Biotechnology Co., Ltd. 15.3.13. Bio-Med Pvt. Ltd. 15.3.14. Chongqing Zhifei Biological Products Co., Ltd. 15.3.15. Hualan Biological Engineering, Inc. 15.3.16. Incepta Pharmaceuticals Ltd. 16. Primary Key Insights

About This Report

Report ID 39058
Category Medical Devices
Published Date Dec 2019
Updated Date Nov 2020
Contact Us